Josep Lluis Parra-Palau
Overview
Explore the profile of Josep Lluis Parra-Palau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parra-Palau J, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, et al.
J Natl Cancer Inst
. 2014 Sep;
106(11).
PMID: 25253614
Human epidermal growth factor receptor 2 (HER2)-positive breast cancers are currently treated with trastuzumab, an anti-HER2 antibody. About 30% of these tumors express a group of HER2 fragments collectively known...
2.
Angelini P, Zacarias Fluck M, Pedersen K, Parra-Palau J, Guiu M, Bernado Morales C, et al.
Cancer Res
. 2013 Jan;
73(1):450-8.
PMID: 23288917
Senescence, a terminal cell proliferation arrest, can be triggered by oncogenes. Oncogene-induced senescence is classically considered a tumor defense barrier. However, several findings show that, under certain circumstances, senescent cells...
3.
Arribas J, Baselga J, Pedersen K, Parra-Palau J
Cancer Res
. 2011 Feb;
71(5):1515-9.
PMID: 21343397
A subtype of HER2-positive tumors with distinct biological and clinical features expresses a series of carboxy-terminal fragments collectively known as p95HER2. One of these fragments, named 100- to 115-kDa p95HER2...
4.
Parra-Palau J, Pedersen K, Peg V, Scaltriti M, Angelini P, Escorihuela M, et al.
Cancer Res
. 2010 Oct;
70(21):8537-46.
PMID: 20978202
Current classification of breast cancers depends in great part on the expression of human epidermal growth factor receptor 2 (HER2), a cell surface tyrosine kinase receptor, and estrogen receptor (ER),...
5.
Arribas J, Parra-Palau J, Pedersen K
Clin Cancer Res
. 2010 Aug;
16(16):4071-3.
PMID: 20682714
HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as...
6.
Garcia-Castillo J, Pedersen K, Angelini P, Bech-Serra J, Colome N, Cunningham M, et al.
J Biol Chem
. 2009 Jul;
284(37):25302-13.
PMID: 19589785
A group of breast cancer patients with a higher probability of developing metastasis expresses a series of carboxyl-terminal fragments (CTFs) of the tyrosine kinase receptor HER2. One of these fragments,...
7.
Pedersen K, Angelini P, Laos S, Bach-Faig A, Cunningham M, Ferrer-Ramon C, et al.
Mol Cell Biol
. 2009 Apr;
29(12):3319-31.
PMID: 19364815
HER2 is a tyrosine kinase receptor causally involved in cancer. A subgroup of breast cancer patients with particularly poor clinical outcomes expresses a heterogeneous collection of HER2 carboxy-terminal fragments (CTFs)....